We are live on ! Find out more
EPZM

Epizyme, Inc

Delisted

EPZM was delisted on the 11th of August, 2022.

160 hedge funds and large institutions have $1.5B invested in Epizyme, Inc in 2020 Q2 according to their latest regulatory filings, with 39 funds opening new positions, 68 increasing their positions, 35 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,448% more call options, than puts

Call options by funds: $59.2M | Put options by funds: $3.83M

94% more repeat investments, than reductions

Existing positions increased: 68 | Existing positions reduced: 35

86% more first-time investments, than exits

New positions opened: 39 | Existing positions closed: 21

12% more funds holding

Funds holding: 143160 (+17)

11% more funds holding in top 10

Funds holding in top 10: 910 (+1)

4% more capital invested

Capital invested by funds: $1.44B → $1.5B (+$63.6M)

Holders
160
Holders Change
+17
Holders Change %
+11.89%
% of All Funds
3.27%
Holding in Top 10
10
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+11.11%
% of All Funds
0.2%
New
39
Increased
68
Reduced
35
Closed
21
Calls
$59.2M
Puts
$3.83M
Net Calls
+$55.4M
Net Calls Change
+$12.4M

EPZM Hedge Fund Activity: Q2 2020 in Review

160 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in Epizyme, Inc (EPZM) for Q2 2020, worth a combined $1.5B — up 4.4% from $1.44B a quarter earlier.

Buyers outnumbered sellers: 39 funds opened new EPZM positions and 21 closed out — a net gain of 18 holders — while 68 added to existing stakes and 35 trimmed.

The largest buyer was Primecap Management, adding an estimated $26M. The largest seller was NEA Management Company, exiting entirely with an estimated $67.9M sold.

  • 160 institutional investors held Epizyme, Inc (EPZM) as of Q2 2020, up from 143 in Q1 2020.
  • Funds reported $1.5B of Epizyme, Inc stock for Q2 2020, up 4.4% quarter-over-quarter.
  • 39 funds opened new Epizyme, Inc positions in Q2 2020 and 21 closed out, a net change of +18 holders.
  • The largest Epizyme, Inc buyer in Q2 2020 was Primecap Management, an estimated $26M added.
  • The largest Epizyme, Inc seller in Q2 2020 was NEA Management Company, an estimated $67.9M sold.

Based on aggregated 13F filings for Q2 2020.